Softwr

Healthcare · head to head

Paige vs Techcyte

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite
Techcyte logo

Techcyte

Healthcare

AI digital pathology across clinical, veterinary and environmental laboratory disciplines

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; Techcyte regulatory status runs the opposite way to what most buyers assume: the products are CE marked and clinically deployed in Europe while several United States offerings including Fusion Parasitology are labelled research use only and not for diagnostic use, so an American laboratory must verify each module individually.
  • They diverge on capability: Paige covers Paige Prostate Detect, Techcyte covers Fusion Parasitology Suite.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and Techcyte actually diverge.

Attributes where Paige and Techcyte differ
AttributePaigeTechcyte
PlatformsWeb, Cloud, On-premiseWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in Techcyte

  • Fusion Parasitology Suite
  • Cervical cytology
  • Haematology
  • Urinalysis
  • Bacteriology and mycology
  • Vetcyte
  • Scanner agnostic ingestion
  • Remote review

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Techcyte
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Techcyte
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Techcyte
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Techcyte

Techcyte

  • A clinical laboratory that cannot recruit technologists for high volume manual parasitology screening and needs AI pre screening with human releasenot Paige
  • A veterinary reference laboratory processing large volumes of faecal and blood smears that wants Vetcyte to triage the normal casesnot Paige
  • A European laboratory that can deploy the CE marked products clinically, which is where Techcyte regulatory position is strongestnot Paige
  • An environmental testing laboratory needing consistent microscopy classification across analysts and sitesnot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Techcyte

  • Regulatory status runs the opposite way to what most buyers assume: the products are CE marked and clinically deployed in Europe while several United States offerings including Fusion Parasitology are labelled research use only and not for diagnostic use, so an American laboratory must verify each module individually.
  • Slide scanning for parasitology, haematology and cytology needs multi plane imaging that a histology scanner may not produce, so a laboratory that already owns a scanner often has to buy new hardware, which becomes the biggest line in the project.
  • Each discipline is licensed separately, so a laboratory wanting parasitology, urinalysis and haematology assembles three modules and three validation studies rather than buying one platform.
  • AI pre screening does not remove the need for a qualified reviewer to release results, so the staffing saving is in review time per slide, not in headcount, and business cases that assume otherwise do not hold.
  • Techcyte covers a very wide set of disciplines, which means depth varies between them, and the maturity of a newer module is not the maturity of the parasitology or cytology products that made the company its name.

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Techcyte

On request
  • Techcyte$undefined/year
    • Priced per slide or per annual specimen volume by discipline
    • Each discipline module licensed separately
    • Slide scanning hardware bought separately, not included

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Choose Techcyte if

  • You need fusion parasitology suite.
  • You also want cervical cytology.
Techcyte review

Questions people ask

Is Paige or Techcyte better?
Neither clearly leads. Paige starts at On request and Techcyte at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or Techcyte?
Paige starts at On request and Techcyte at On request.
Does Paige or Techcyte run on more platforms?
Paige runs on Web, Cloud, On-premise. Techcyte runs on Web.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what Techcyte is typically brought in for.
What can Paige do that Techcyte cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications. Techcyte covers Fusion Parasitology Suite, Cervical cytology, Haematology, Urinalysis.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Techcyte: Is Techcyte FDA cleared?

Not uniformly. Several United States offerings, including the Fusion Parasitology Suite, are labelled research use only and not for diagnostic use in the United States. Check the regulatory status of each specific module for your country before purchase.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Techcyte: Can we use it clinically in Europe?

Techcyte solutions are CE marked and clinically deployed across Europe, which is where its regulatory position is strongest. Confirm the current certificate for the specific module.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Techcyte: Does it eliminate the need for a technologist?

No. AI pre screens and prioritises, but a qualified reviewer still releases results. The saving is in review time per slide.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Techcyte: Do we need a specific scanner?

Techcyte works with several scanner vendors, but disciplines such as parasitology and haematology need multi plane imaging that many histology scanners cannot produce, so confirm hardware compatibility early.

Share

Related pages

More on Paige

More on Techcyte

Keep looking

Other head to heads